Shares of Irvine heart valve maker Edwards Lifesciences Corp. rose today after it said it expects strong sales for its less-invasive heart valves next year.

Edwards’ shares rose nearly 6% to a market value of $10.6 billion.

The company said at an investor conference that it expects 2013 sales of its less-invasive Edwards Sapien heart valve line to come in at $710 million to $790 million, up from its 2012 projection of $560 million to $630 million.

Transcatheter heart valves have accounted for $391.1 million in sales through the first nine months of 2012 for Edwards.